Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients: A Meta-analysis | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Lim  WS, Macfarlane  JT, Boswell  TC,  et al.  Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.  Thorax. 2001;56(4):296-301.PubMedGoogle ScholarCrossref
2.
Rubin  MA, Ford  LC, Gonzales  R. Pharyngitis, sinusitis, otitis, and other upper respiratory tract infections. In: Longo  DL, Fauci  AS, Kasper  DL, Hauser  SL, Jameson  JL, Loscalzo  J, eds.  Harrison's Principles of Internal Medicine.18th ed. New York, NY: McGraw-Hill; 2012.
3.
Smeeth  L, Thomas  SL, Hall  AJ, Hubbard  R, Farrington  P, Vallance  P.  Risk of myocardial infarction and stroke after acute infection or vaccination.  N Engl J Med. 2004;351(25):2611-2618.PubMedGoogle ScholarCrossref
4.
Nichol  KL, Margolis  KL, Wuorenma  J, Von Sternberg  T.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.  N Engl J Med. 1994;331(12):778-784.PubMedGoogle ScholarCrossref
5.
Bainton  D, Jones  GR, Hole  D.  Influenza and ischaemic heart disease—a possible trigger for acute myocardial infarction?  Int J Epidemiol. 1978;7(3):231-239.PubMedGoogle ScholarCrossref
6.
Madjid  M, Aboshady  I, Awan  I, Litovsky  S, Casscells  SW.  Influenza and cardiovascular disease: is there a causal relationship?  Tex Heart Inst J. 2004;31(1):4-13.PubMedGoogle Scholar
7.
Warren-Gash  C, Smeeth  L, Hayward  AC.  Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review.  Lancet Infect Dis. 2009;9(10):601-610.PubMedGoogle ScholarCrossref
8.
Warren-Gash  C, Bhaskaran  K, Hayward  A,  et al.  Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong.  J Infect Dis. 2011;203(12):1710-1718.PubMedGoogle ScholarCrossref
9.
Corrales-Medina  VF, Musher  DM, Shachkina  S, Chirinos  JA.  Acute pneumonia and the cardiovascular system.  Lancet. 2013;381(9865):496-505.PubMedGoogle ScholarCrossref
10.
Naghavi  M, Barlas  Z, Siadaty  S, Naguib  S, Madjid  M, Casscells  W.  Association of influenza vaccination and reduced risk of recurrent myocardial infarction.  Circulation. 2000;102(25):3039-3045.PubMedGoogle ScholarCrossref
11.
Siscovick  DS, Raghunathan  TE, Lin  D,  et al.  Influenza vaccination and the risk of primary cardiac arrest.  Am J Epidemiol. 2000;152(7):674-677.PubMedGoogle ScholarCrossref
12.
Lavallée  P, Perchaud  V, Gautier-Bertrand  M, Grabli  D, Amarenco  P.  Association between influenza vaccination and reduced risk of brain infarction.  Stroke. 2002;33(2):513-518.PubMedGoogle ScholarCrossref
13.
Nichol  KL, Nordin  J, Mullooly  J, Lask  R, Fillbrandt  K, Iwane  M.  Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.  N Engl J Med. 2003;348(14):1322-1332.PubMedGoogle ScholarCrossref
14.
Grau  AJ, Fischer  B, Barth  C, Ling  P, Lichy  C, Buggle  F.  Influenza vaccination is associated with a reduced risk of stroke.  Stroke.2005;36(7):1501-1506. PubMedGoogle ScholarCrossref
15.
Madjid  M, Miller  CC, Zarubaev  VV,  et al.  Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects.  Eur Heart J. 2007;28(10):1205-1210.PubMedGoogle ScholarCrossref
16.
Nichol  KL, Nordin  JD, Nelson  DB, Mullooly  JP, Hak  E.  Effectiveness of influenza vaccine in the community-dwelling elderly.  N Engl J Med. 2007;357(14):1373-1381.PubMedGoogle ScholarCrossref
17.
Hung  IF, Leung  AY, Chu  DW,  et al.  Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study.  Clin Infect Dis. 2010;51(9):1007-1016.PubMedGoogle ScholarCrossref
18.
Siriwardena  AN, Gwini  SM, Coupland  CA.  Influenza vaccination, pneumococcal vaccination, and risk of acute myocardial infarction: matched case-control study.  CMAJ. 2010;182(15):1617-1623.PubMedGoogle ScholarCrossref
19.
Macintyre  CR, Heywood  AE, Kovoor  P,  et al.  Ischaemic heart disease, influenza, and influenza vaccination: a prospective case control study.  Heart. 2013.PubMedGoogle Scholar
20.
Gurfinkel  EP, de la Fuente  RL, Mendiz  O, Mautner  B.  Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study.  Circulation. 2002;105(18):2143-2147.PubMedGoogle ScholarCrossref
21.
Gurfinkel  EP, Leon de la Fuente  R, Mendiz  O, Mautner  B.  Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study.  Eur Heart J. 2004;25(1):25-31.PubMedGoogle ScholarCrossref
22.
Ciszewski  A, Bilinska  ZT, Brydak  LB,  et al.  Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study.  Eur Heart J. 2008;29(11):1350-1358.PubMedGoogle ScholarCrossref
23.
Ciszewski  A, Bilińska  ZT, Kepka  C, Kruk  M, Księżycka-Majczyńska  E, Rużyłło  W.  The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI—a report from FLUCAD study.  Postępy w Kardiologii Interwencyjnej.2010;6(1):6-11. doi:10.5114/pwki.2010.13820.Google Scholar
24.
Phrommintikul  A, Kuanprasert  S, Wongcharoen  W, Kanjanavanit  R, Chaiwarith  R, Sukonthasarn  A.  Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome.  Eur Heart J. 2011;32(14):1730-1735.PubMedGoogle ScholarCrossref
25.
Harper  SA, Fukuda  K, Uyeki  TM, Cox  NJ, Bridges  CB.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep.2005;54(RR-8):1-40. PubMedGoogle Scholar
26.
Goldstein  LB, Bushnell  CD, Adams  RJ,  et al.  Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.  Stroke.2011;42(2):517-584. PubMedGoogle ScholarCrossref
27.
Advisory Committee on Immunization Practices.  Recommended adult immunization schedule: United States, 2013.  Ann Intern Med. 2013;158(3):191-199.PubMedGoogle ScholarCrossref
28.
Smith  SC, Allen  J, Blair  SN,  et al; AHA/ACC; National Heart, Lung, and Blood Institute.  AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update.  Circulation.2006;113(19):2363-2372. PubMedGoogle ScholarCrossref
29.
Davis  MM, Taubert  K, Benin  AL,  et al; American Heart Association; American College of Cardiology.  Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology.  Circulation. 2006;114(14):1549-1553.PubMedGoogle ScholarCrossref
30.
Smith  SC  Jr, Benjamin  EJ, Bonow  RO,  et al; World Heart Federation; Preventive Cardiovascular Nurses Association.  AHA/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.  Circulation. 2011;124(22):2458-2473.PubMedGoogle ScholarCrossref
31.
Hamm  CW, Bassand  JP, Agewall  S,  et al; ESC Committee for Practice Guidelines.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).  Eur Heart J. 2011;32(23):2999-3054.PubMedGoogle ScholarCrossref
32.
Hashim  AB, McKeever  T, Kelly  SJ, Nguyen-Van-Tam  JS.  Evaluation of inter-pandemic influenza vaccine effectiveness during 8 consecutive winter seasons in England and Wales in patients with cardiovascular risk factors.  J Infect Public Health. 2010;3(4):159-165.PubMedGoogle ScholarCrossref
33.
Eurich  DT, Marrie  TJ, Johnstone  J, Majumdar  SR.  Mortality reduction with influenza vaccine in patients with pneumonia outside “flu” season: pleiotropic benefits or residual confounding?  Am J Respir Crit Care Med. 2008;178(5):527-533.PubMedGoogle ScholarCrossref
34.
Johnstone  J, Loeb  M, Teo  KK,  et al; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators.  Influenza vaccination and major adverse vascular events in high-risk patients.  Circulation. 2012;126(3):278-286.PubMedGoogle ScholarCrossref
35.
Keller  T, Weeda  VB, van Dongen  CJ, Levi  M.  Influenza vaccines for preventing coronary heart disease.  Cochrane Database Syst Rev. 2008;(3):CD005050.PubMedGoogle Scholar
36.
Loomba  RS, Aggarwal  S, Shah  PH, Arora  RR.  Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292 383 patients.  J Cardiovasc Pharmacol Ther. 2012;17(3):277-283.PubMedGoogle ScholarCrossref
37.
Centers for Disease Control and Prevention.  Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
38.
World Health Organization. Global atlas of infectious diseases. http://gamapserver.who.int/globalatlas/home.asp. Accessed September 19, 2013.
39.
Higgins  JP, Altman  DG, Gøtzsche  PC,  et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.  BMJ. 2011;343:5928.PubMedGoogle ScholarCrossref
40.
Keshtkar-Jahromi  M, Vakili  H, Rahnavardi  M,  et al.  The efficacy of influenza vaccination in reducing cardiovascular events in patients with coronary artery diseases: IVCAD study.  Clin Microbiol Infect. 2009;15:395.Google ScholarCrossref
41.
Govaert  TM, Thijs  CT, Masurel  N, Sprenger  MJ, Dinant  GJ, Knottnerus  JA.  The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial.  JAMA.1994;272(21):1661-1665. PubMedGoogle ScholarCrossref
42.
De Villiers  PJ, Steele  AD, Hiemstra  LA,  et al; LAIV Elderly Study Trial Network.  Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.  Vaccine. 2009;28(1):228-234.PubMedGoogle ScholarCrossref
43.
Jackson  LA, Holmes  SJ, Mendelman  PM, Huggins  L, Cho  I, Rhorer  J.  Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions.  Vaccine. 1999;17(15-16):1905-1909.PubMedGoogle ScholarCrossref
44.
de Bruijn  IA, Nauta  J, Cramer  WC, Gerez  L, Palache  AM.  Clinical experience with inactivated, virosomal influenza vaccine.  Vaccine. 2005;23(suppl 1):39-49.PubMedGoogle ScholarCrossref
45.
Gaughran  F, Walwyn  R, Lambkin-Williams  R,  et al; Flu-Effect of Vaccine in Elderly Residents Trial team.  Flu: effect of vaccine in elderly care home residents: a randomized trial.  J Am Geriatr Soc. 2007;55(12):1912-1920.PubMedGoogle ScholarCrossref
46.
Falsey  AR, Treanor  JJ, Tornieporth  N, Capellan  J, Gorse  GJ.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.  J Infect Dis. 2009;200(2):172-180.PubMedGoogle ScholarCrossref
47.
Forrest  BD, Steele  AD, Hiemstra  L, Rappaport  R, Ambrose  CS, Gruber  WC.  A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.  Vaccine. 2011;29(20):3633-3639.PubMedGoogle ScholarCrossref
48.
DiazGranados  CA, Dunning  AJ, Jordanov  E, Landolfi  V, Denis  M, Talbot  HK.  High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.  Vaccine. 2013;31(6):861-866.PubMedGoogle ScholarCrossref
49.
Jadad  AR, Moore  RA, Carroll  D,  et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?  Control Clin Trials. 1996;17(1):1-12.PubMedGoogle ScholarCrossref
50.
Moher  D, Liberati  A, Tetzlaff  J, Altman  DG; PRISMA Group.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.  BMJ. 2009;339:2535.PubMedGoogle ScholarCrossref
51.
DerSimonian  R, Laird  N.  Meta-analysis in clinical trials.  Control Clin Trials. 1986;7(3):177-188.PubMedGoogle ScholarCrossref
52.
Cox  DR.  The continuity correction.  Biometrika.1970;57(1):  et al-219. doi: 10.1093/biomet/57.1.217.Google Scholar
53.
Friedrich  JO, Adhikari  NK, Beyene  J.  Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data.  BMC Med Res Methodol. 2007;7:5.PubMedGoogle ScholarCrossref
54.
Higgins  JP, Thompson  SG.  Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;21(11):1539-1558.PubMedGoogle ScholarCrossref
55.
Sterne  JA, Sutton  AJ, Ioannidis  JP,  et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.  BMJ. 2011;343:4002.PubMedGoogle ScholarCrossref
56.
Altman  DG, Bland  JM.  Interaction revisited: the difference between 2 estimates.  BMJ. 2003;326(7382):219.PubMedGoogle ScholarCrossref
57.
Bratincsák  A, El-Said  HG, Bradley  JS, Shayan  K, Grossfeld  PD, Cannavino  CR.  Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children.  J Am Coll Cardiol. 2010;55(9):928-929.PubMedGoogle ScholarCrossref
58.
Muhammad  S, Haasbach  E, Kotchourko  M,  et al.  Influenza virus infection aggravates stroke outcome.  Stroke.2011;42(3):783-791. PubMedGoogle ScholarCrossref
59.
Natarajan  P, Cannon  CP.  Myocardial infarction vaccine? evidence supporting the influenza vaccine for secondary prevention.  Eur Heart J. 2011;32(14):1701-1703.PubMedGoogle ScholarCrossref
60.
Ajani  UA, Ford  ES, Mokdad  AH.  Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States.  Am Heart J. 2005;149(2):254-259.PubMedGoogle ScholarCrossref
61.
Kwong  JC, Rosella  LC, Johansen  H.  Trends in influenza vaccination in Canada, 1996/1997 to 2005.  Health Rep.2007;18(4):9-19. PubMedGoogle Scholar
62.
Madjid  M, Alfred  A, Sahai  A, Conyers  JL, Casscells  SW.  Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease.  Tex Heart Inst J. 2009;36(6):546-552.PubMedGoogle Scholar
63.
Williams  WW, Lu  PJ, Lindley  MC, Kennedy  ED, Singleton  JA; Centers for Disease Control and Prevention.  Influenza vaccination coverage among adults—National Health Interview Survey, United States, 2008-09 influenza season.  MMWR Morb Mortal Wkly Rep. 2012;61(suppl):65-72.PubMedGoogle Scholar
64.
Talbot  TR, Talbot  HK.  Influenza prevention update: examining common arguments against influenza vaccination.  JAMA. 2013;309(9):881-882.PubMedGoogle ScholarCrossref
65.
Dolin  R. Influenza. In: Longo  DL, Fauci  AS, Kasper  DL, Hauser  SL, Jameson  JL, Loscalzo  J, eds.  Harrison's Principles of Internal Medicine.18th ed. New York, NY: McGraw-Hill; 2012.
66.
Ungchusak  K, Sawanpanyalert  P, Hanchoworakul  W,  et al.  Lessons learned from influenza A(H1N1)pdm09 pandemic response in Thailand.  Emerg Infect Dis. 2012;18(7):1058-1064.PubMedGoogle ScholarCrossref
67.
Centers for Disease Control and Prevention. 2012-2013 Influenza Season Week 38 ending September 21, 2013. http://www.cdc.gov/flu/weekly/. Accessed September 28, 2013.
Original Investigation
October 23/30, 2013

Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients: A Meta-analysis

Author Affiliations
  • 1Women’s College Research Institute and Cardiovascular Division, Department of Medicine, Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada
  • 2Medical University of the Americas, Nevis, West Indies
  • 3VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts
  • 4Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 5Clinical Research and Development Center, Shahid Modarres Medical Center, Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University (MC), Tehran, Iran
  • 6Division of Infectious Disease, Department of Medicine, Pennsylvania State University School of Medicine, Hershey
  • 7Institute of Psychiatry, King’s College London, London, United Kingdom
  • 8South London and Maudsley National Health Service Foundation Trust, London, United Kingdom
  • 9Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • 10Institute of Cardiology, Warsaw, Poland
  • 11Cardiovascular Research Center, Shahid Modarres Medical Center, Shahid Beheshti University (MC), Tehran, Iran
  • 12Peter Munk Cardiac Centre, University Health Network, Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada
JAMA. 2013;310(16):1711-1720. doi:10.1001/jama.2013.279206
Abstract

Importance  Among nontraditional cardiovascular risk factors, recent influenzalike infection is associated with fatal and nonfatal atherothrombotic events.

Objectives  To determine if influenza vaccination is associated with prevention of cardiovascular events.

Data Sources and Study Selection  A systematic review and meta-analysis of MEDLINE (1946-August 2013), EMBASE (1947-August 2013), and the Cochrane Library Central Register of Controlled Trials (inception-August 2013) for randomized clinical trials (RCTs) comparing influenza vaccine vs placebo or control in patients at high risk of cardiovascular disease, reporting cardiovascular outcomes either as efficacy or safety events.

Data Extraction and Synthesis  Two investigators extracted data independently on trial design, baseline characteristics, outcomes, and safety events from published manuscripts and unpublished supplemental data. High-quality studies were considered those that described an appropriate method of randomization, allocation concealment, blinding, and completeness of follow-up.

Main Outcomes and Measures  Random-effects Mantel-Haenszel risk ratios (RRs) and 95% CIs were derived for composite cardiovascular events, cardiovascular mortality, all-cause mortality, and individual cardiovascular events. Analyses were stratified by subgroups of patients with and without a history of acute coronary syndrome (ACS) within 1 year of randomization.

Results  Five published and 1 unpublished randomized clinical trials of 6735 patients (mean age, 67 years; 51.3% women; 36.2% with a cardiac history; mean follow-up time, 7.9 months) were included. Influenza vaccine was associated with a lower risk of composite cardiovascular events (2.9% vs 4.7%; RR, 0.64 [95% CI, 0.48-0.86], P = .003) in published trials. A treatment interaction was detected between patients with (RR, 0.45 [95% CI, 0.32-0.63]) and without (RR, 0.94 [95% CI, 0.55-1.61]) recent ACS (P for interaction = .02). Results were similar with the addition of unpublished data.

Conclusions and Relevance  In a meta-analysis of RCTs, the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events. The greatest treatment effect was seen among the highest-risk patients with more active coronary disease. A large, adequately powered, multicenter trial is warranted to address these findings and assess individual cardiovascular end points.

×